For 328 Patients With Gastroesophageal Reflux Disease
Demonstrates Non-Inferiority to Existing Treatment

Daewon Pharmaceutical's novel treatment for gastroesophageal reflux disease, Padoprazan (DW4421), a potassium-competitive acid blocker (P-CAB), met the primary efficacy endpoint in a domestic Phase 3 clinical trial.


According to Daewon Pharmaceutical on October 29, the Phase 3 trial was conducted to evaluate the efficacy and safety of Padoprazan in patients with erosive gastroesophageal reflux disease (ERD). A total of 328 patients at 22 medical institutions in South Korea were enrolled, and the Padoprazan 20 mg and 40 mg groups were compared with a group receiving 40 mg of esomeprazole, an existing proton pump inhibitor (PPI).

Daewon Pharmaceutical's P-CAB Drug Succeeds in Phase 3 Trial... Plans Approval Application This Year View original image

The primary efficacy endpoint was complete healing of esophageal mucosal defects confirmed by endoscopy. The trial assessed whether the lower bound of the two-sided 95% confidence interval for the difference in efficacy rates between the Padoprazan and esomeprazole groups exceeded the prespecified non-inferiority margin of -10.0%.


The results showed that the 95% confidence interval for the difference in efficacy rates between the Padoprazan 40 mg group and the control group was -2.50% to 6.87%, while that for the 20 mg group was -3.90% to 6.58%. The lower bounds for both doses met the non-inferiority criterion, demonstrating non-inferiority to esomeprazole.


The incidence of adverse drug reactions was 4.59% in the Padoprazan 40 mg group, 3.74% in the 20 mg group, and 3.70% in the esomeprazole group. There was no statistically significant difference in incidence rates among the groups, and no serious adverse events occurred.


Based on these topline results, Daewon Pharmaceutical plans to conduct detailed analyses of efficacy and safety, submit the final clinical study report to the Ministry of Food and Drug Safety within the year, and apply for product approval. A Phase 3 trial in patients with non-erosive gastroesophageal reflux disease (NERD) is also underway, and the company is preparing clinical trials to obtain additional indications.



A Daewon Pharmaceutical official said, "We will proceed with detailed analyses and the product approval process without delay, and work to provide patients with gastroesophageal reflux disease with a new treatment option."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing